Over the last 30 days, the NOVARTIS share price is down 1.9%. Fds.

Novartis AG Common Stock (NVS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Covid-19 Proof Multibagger Stocks - Download this FREE Report Now.

Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group.

This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. These Companies Are Seeking a Cure for Sickle Cell. Novartis Share Price Live - 668.55, Novartis Stock Price, Today - The Economic Times.

Novartis stock trades at nearly a 20% discount to its pharma sector, yet she expects new products to drive its annual earnings growth at an above-average 9%. On September 01, 2020, we introduced a new Code of Ethics for Novartis.

Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Data may be intentionally delayed pursuant to supplier requirements. For more details, see the Novartis company fact sheet and quarterly results.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. Novartis stock outlook.

Source: Kantar Media, News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2020© Refinitiv. The stock may not take off just yet, but over the long term, there's a great opportunity for investors to earn some strong returns from owning shares of Novartis. International stock quotes are delayed as per exchange requirements. Copyright 2020 FactSet Research Systems Inc. All rights reserved.

INH000000537. How to Save Money by Exiting Stocks Before They Fall, A Contrarian View on Whether You Should Load Up on Small Caps.

The performance data quoted represents past performance and does not guarantee future results. AstraZeneca Made a Bid for Gilead, According to Reports, Astrazeneca’s Strong First Quarter Shows The Stock Can Weather The Coronavirus Storm, Regeneron Stock Has Hit Its Peak, Says Citi, Big Pharma Sees Its Strengths Surface in the Pandemic, EMA Accepts Biogen, Samsung Bioepis Filing for Lucentis Biosimilar, Merck KGaA to Outlicense Osteoarthritis Clinical Program for Up to EUR450 Mln, WSJ Wealth Adviser Briefing: Reason for Investors to Look Away, Private Debt, Athletes Conquer Distance, Companies Test a New Type of ESG Bond With Fewer Restrictions, Where a Unilever Cosmetics Exec Established Her Foundation, FDA broadens U.S. safety inquiry into AstraZeneca COVID-19 vaccine, report says, raising prospect of further delays, Sustainable-Bond Market Boosted by Europe’s Top Institutions, A Bet on Europe Is a Bet on Drugs, Against Tech, BioNTech to Buy German Novartis Site to Expand Covid-19 Vaccine Production, Gilead Reaches Deal to Buy Immunomedics for $21 Billion, The Federal Program That Keeps Insulin Prices High, Novartis, Roche, Genentech Get Joint EUR444 Mln Fine From French Antitrust Authority -- Update, Novartis, Roche, Genentech Get Joint EUR444 Mln Fine From French Antitrust Authority, Teva’s Indictment Came After Talks Faltered With Justice Department, Teva Pharmaceutical’s U.S. Unit Indicted on Price-Fixing Charges, Drug maker Teva’s U.S. unit indicted on price-fixing charges, Novartis's Spartalizumab Phase 3 Combi-i Trial Didn't Meet Primary Endpoint, Novartis: Multiple-Sclerosis Drug Kesimpta Gets FDA Approval, Novartis's Gilenya Dosage Regimen Patent Upheld in US Court Decision, Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US, Franklin Mutual Ser. Novartis India Ltd.Board Meeting Intimation for Considering The Unaudited Financial Results Of The Company For The First Quarter Ended June... Novartis India Ltd.Statement Of Investor Complaints For The Quarter Ended June 2020, Novartis India Ltd.Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2020. Telephone: +91-22-61434055.

Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Dig in... Indian share markets witnessed buying interest during the last hour of trading yesterday and ended near day's high.

Novartis India Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 399.65 Crore to Sales Value (91.19 % of Total Sales), Commission which contributed Rs 26.12 Crore to Sales Value (5.96 % of Total Sales), Sale of services which contributed Rs 11.70 Crore to Sales Value (2.66 % of Total Sales) and Other Operating Revenue which contributed Rs .78 Crore to Sales Value (0.17 % of Total Sales)for the year ending 31-Mar-2020. {{HLdata.Fifty2WkHigh_adj|number:2}}{{HLdata.Fifty2WkHigh_adjDt}}, {{HLdata.Fifty2WkLow_adj|number:2}}{{HLdata.Fifty2WkLow_adjDt}}, If you have RSS reader, Please Cut and Paste the URL.

Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. When autocomplete results are available use up and down arrows to review and enter to select. Nifty 11,914.20 79.6. Are You Making One of These 15 Costly Mistakes While Investing. Equitymaster is not an Investment Adviser. Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Data may be intentionally delayed pursuant to supplier requirements. And over the last one year, NOVARTIS share price is up 6.3%. What else is happening in the markets today? Novartind financial results, Novartind shareholding, Novartind annual reports, Novartind pledge, Novartind insider trading and compare with peer companies. Lilly, J&J, Amgen, and Gilead Stand to Gain. Before it's here, it's on the Bloomberg Terminal.

Learn More.

Top Loser for the period amongst the peers, Top Gainer for the period amongst the peers. Equitymaster may hold shares in the company/ies discussed herein.

What's your view on Novartis India for the week? Wipro 374.00 14.55. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. For reprint rights: We will never share or display your Email. Read on for a complete analysis of NOVARTIS's quarterly results. Source: FactSet Fundamentals. How I picked an exciting stock using trends from both the commodity and equity markets. Multibagger Stocks. Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time.

Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster. All rights reserved. Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. *Trailing 12 months earnings, excluding extraordinary / exceptional items. Dow Jones Industrial Average Rises on Europe’s Massive Recovery Plan, Novartis Stock Falls as Swiss Drugmaker Cuts Sales Outlook on Pandemic Woes, Tesla, AT&T, Microsoft, Intel, and Other Stocks for Investors to Watch This Week, The 2020 New York City Marathon Sets a Virtual Plan With Strava, Buy Regeneron Stock, but Not Because of Its Covid-19 Antibody Cocktail, Regeneron Used a Charity to Pay Kickbacks, Justice Department Alleges, Lilly Stock Has a 10% Upside, Guggenheim Says.